Skip to main content

Preface [Hot Topic: Anticoagulation: Current and Future Therapies (Guest Editors: Jean-Marie Stassen / Uwe Joerg Ries)]

Buy Article:

$63.00 plus tax (Refund Policy)


Cardiovascular diseases, including thromboembolic diseases associated with the western life style are major causes of morbidity and mortality in our society.

The major components of hemostatic system are thrombocytes, the coagulation proteins and the fibrinolytic system. Therapies for thromboembolic diseases are based on different approaches depending on the site in the vascular system that is at risk when the disease occurs.

Antithrombotic therapy has progressed enormously over the last two decades. Enormous attention from academic as well as pharma companies and biotech industry has resulted in novel agents for the prevention and treatment of thromboembolic diseases (Reopro, Clopidogrel, low molecular weight heparins, Exanta, Actilyse). As evidenced by the observation that many companies have projects in different stages of discovery and development in their pipeline, current therapy still leaves enough room for the development of novel antiplatelet, anticoagulant, and thrombolytic agents. Attention on the improvement of new agents is focused on but not restricted to the development of more efficient therapies but special focus in this area is also given to the ease of use, no need for therapy monitoring, oral availability, duration of action and the absence of side effects such as bleeding.

Recent developments in drug discovery technology, such as combinatorial chemistry, high throughput screening, molecular modeling, pharmacogenomic guided screening, gene inactivation strategies, new targets as well as enhanced development processes will most probably contribute significantly to the medical therapy in the future. A contemporary overview of the approaches that might lead to novel products and the available literature are reviewed in this issue. Approaches for the development of antiplatelet agents, anticoagulant therapies and profibrinolytic treatments are addressed by the authors. Our special thanks go to the contributors of this issue.

Document Type: Book Review


Affiliations: Thromb-X NV Herestraat 49 B-3000, Leuven, Belgium.

Publication date: 2004-09-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more